Pretreatment PSA Velocity as a Predictor of Disease Outcome Following Radical Radiation Therapy

Conclusion: Pretreatment PSAV greater than 2.0 ng/mL/year is associated with reduced bDFS. However, PSAV is an independent predictor of bDFS only in high-risk patients. PSAV does not predict survival outcomes.